Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
ADIL Adial Pharmaceuticals $1.28 -0.05 (-3.76%) 08:24 11/19/18 11/19 08:24 11/19/18 08:24 Hot Stocks	Adial Pharmaceuticals engages Crown CRO to begin Phase 3 trial for AD04 » Adial Pharmaceuticals and… Adial Pharmaceuticals and Crown CRO, a contract research organization based in Finland, announced Crown's engagement to manage Adial's Phase 3 clinical trial for AD04 for the treatment of alcohol use disorder. The FDA approved protocol for this Phase 3 clinical trial is a 24-week trial with 290 patients in 30 clinical sites in 5 European countries. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
ADIL Adial Pharmaceuticals $1.40 -0.31 (-18.13%) 09:26 11/08/18 11/08 09:26 11/08/18 09:26 Hot Stocks	Adial Pharmaceuticals receives notice of allowance for AD04 patent from CIPO » Adial Pharmaceuticals… Adial Pharmaceuticals announced the further strengthening of its intellectual property portfolio, as it has received a notice of allowance from the Canadian Intellectual Property Office, or CIPO, on its patent for AD04, which covers the genetically targeted use of ondansetron in patients with alcohol use disorder, or AUD. This patent is expected to remain in effect through 2029 with additional Canadian patents pending that are expected to provide protection through 2032. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
ADIL Adial Pharmaceuticals $2.01 (0.00%) 08:04 10/30/18 10/30 08:04 10/30/18 08:04 Initiation	Adial Pharmaceuticals initiated at Maxim » Adial Pharmaceuticals… Adial Pharmaceuticals initiated with a Buy at Maxim. Maxim analyst Jason McCarthy initiated Adial Pharmaceuticals with a Buy rating and a price target of $5, citing the company's development of AD04 - an ultra-low-dose ondansetron therapy for the treatment of alcohol use disorder. The analyst notes that the phase 2b study has already demonstrated a "reduced drinks per day" and "decreased percent heavy drinking days" responses, with phase 3 study expected in the future. McCarthy further cites the large potential under-served market of 35M people in the U.S. suffering from alcohol use disorder. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
ADIL Adial Pharmaceuticals $2.01 (0.00%) 08:03 10/30/18 10/30 08:03 10/30/18 08:03 Initiation	Adial Pharmaceuticals initiated at Maxim » Adial Pharmaceuticals… Adial Pharmaceuticals initiated with a Buy at Maxim. Maxim analyst Jason McCarthy initiated Adial Pharmaceuticals with a Buy rating and $5 price target, citing his belief that AD04 has potential to have success in the "under-served" alcohol use disorder market. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
ADIL Adial Pharmaceuticals $2.62 (0.00%) 07:24 10/11/18 10/11 07:24 10/11/18 07:24 Initiation	Adial Pharmaceuticals initiated at Dawson James » Adial Pharmaceuticals… Adial Pharmaceuticals initiated with a Buy at Dawson James. Dawson James analyst Carol Werther initiated Adial Pharmaceuticals with a Buy and $6 price target. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

HSDT Helius Medical $9.40 -0.4 (-4.08%) , PDVW pdvWireless $33.93 0.03 (0.09%) … 04:55 10/02/18 10/02 04:55 10/02/18 04:55 Conference/Events	PubCoCEO to hold a conference » MicroCap Conference 2018… MicroCap Conference 2018 will be held in New York on October 1-2. HSDT Helius Medical $9.40 -0.4 (-4.08%) PDVW pdvWireless $33.93 0.03 (0.09%) ADIL Adial Pharmaceuticals $2.76 -0.24 (-8.00%) NAKD Naked Brand Group $2.41 -0.29 (-10.74%) OGEN Oragenics $1.60 0.46 (40.35%) CURR CURE Pharmaceutical $0.00 (0.00%) JTPY JetPay $2.10 0.1 (5.00%) ISDR Issuer Direct $15.31 -0.64 (-4.01%) INPX Inpixon $0.21 0.0031 (1.54%) XXII 22nd Century $2.78 -0.03 (-1.07%) PRLX Parlex Corp. $0.00 (0.00%) KMDA Kamada $6.22 0.065 (1.06%) LMAT LeMaitre $37.24 -1.48 (-3.82%) DXR Daxor $5.44 0.18 (3.42%) SNOA Sonoma Pharmaceuticals $1.54 (0.00%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	02 Oct 04 Oct 04 Oct 05 Oct
ADIL Adial Pharmaceuticals $3.00 (0.00%) 14:32 10/01/18 10/01 14:32 10/01/18 14:32 Initiation	Adial Pharmaceuticals initiated at Dawson James » Adial Pharmaceuticals at… Adial Pharmaceuticals at Dawson James. Dawson James initiated Adial Pharmaceuticals with a Buy and $6 price target. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	01 Oct
HSDT Helius Medical $9.80 0.34 (3.59%) , PDVW pdvWireless $33.90 -1.65 (-4.64%) … 07:24 10/01/18 10/01 07:24 10/01/18 07:24 Conference/Events	PubCoCEO to hold a conference » MicroCap Conference 2018… MicroCap Conference 2018 will be held in New York on October 1-2. HSDT Helius Medical $9.80 0.34 (3.59%) PDVW pdvWireless $33.90 -1.65 (-4.64%) ADIL Adial Pharmaceuticals $3.00 0.03 (1.01%) NAKD Naked Brand Group $2.70 -0.03 (-1.10%) OGEN Oragenics $1.14 0.4225 (58.89%) CURR CURE Pharmaceutical $0.00 (0.00%) JTPY JetPay $2.00 0.2 (11.11%) ISDR Issuer Direct $15.95 0.95 (6.33%) INPX Inpixon $0.20 -0.01 (-4.72%) XXII 22nd Century $2.81 -0.03 (-1.06%) PRLX Parlex Corp. $0.00 (0.00%) KMDA Kamada $6.15 -0.1 (-1.60%) LMAT LeMaitre $38.72 1.23 (3.28%) DXR Daxor $5.26 -0.24 (-4.36%) SNOA Sonoma Pharmaceuticals $1.54 0.04 (2.67%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	01 Oct 01 Oct 02 Oct 04 Oct 04 Oct 05 Oct
ADIL Adial Pharmaceuticals $3.13 0.3 (10.60%) 07:35 09/18/18 09/18 07:35 09/18/18 07:35 Hot Stocks	Adial Pharmaceuticals receives European patent for AD04 » Adial Pharmaceuticals… Adial Pharmaceuticals announced an addition to its intellectual property, or IP portfolio, as it has successfully passed the patent opposition period in Europe without any challenges to its patent for AD04, which was granted by the European Patent Office, or EPO, as EP 2801625 B1 and validated in 36 European countries. With the opposition period having expired, a third party can no longer challenge the validity of EP 2801625 B1 in the EPO. This patent can now only be challenged in the individual national courts of the 36 European countries where it has been validated. The company believes the claims and scope of the patent are highly enforceable and provide broad protection. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a quarter ago
ADIL Adial Pharmaceuticals $2.76 -0.14 (-4.83%) 09:18 09/12/18 09/12 09:18 09/12/18 09:18 Hot Stocks	Adial Pharmaceuticals announces 'successful' stability results for AD04 » Adial Pharmaceuticals… Adial Pharmaceuticals announced "successful" results related to the stability testing of the clinical trial material for its lead drug candidate, AD04, a genetically targeted therapeutic agent being developed to treat alcohol use disorder. The program indicated stability at the four-year time point for both the active drug candidate and the placebo tablets that had been previously manufactured for use in clinical trials. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial